Praluent® (alirocumab) – New and expanded indications
April 26, 2019 - Regeneron and Sanofi announced the FDA approval of Praluent (alirocumab), to reduce the risk of myocardial infarction (MI), stroke, and unstable angina requiring hospitalization in adults with established cardiovascular (CV) disease.
Top